Rezolute (RZLT) Non-Current Assets (2012 - 2026)
Rezolute recorded quarterly Non-Current Assets of $3.4 million in Q1 2026, down 3.21% quarter-over-quarter from $3.5 million in Q4 2025, and down 43.2% year-over-year from $6.0 million in Q1 2025.
Rezolute's Non-Current Assets history runs 15 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 43.2% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $15.2 million (down 58.42% YoY), while the FY2025 annual figure was $4.3 million, up 6.39% from the prior year.
- Non-Current Assets came in at $3.4 million for Q1 2026 at Rezolute, down from $3.5 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $28.7 million in Q1 2023 to a low of $316000.0 in Q2 2022.
- A 5-year average of $7.6 million and a median of $5.2 million in 2022 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets surged 5852.85% in 2023 and plunged 80.73% in 2024, its largest moves.
- Rezolute's Non-Current Assets stood at $2.6 million in 2022, then soared by 133.09% to $6.1 million in 2023, then jumped by 119.51% to $13.3 million in 2024, then tumbled by 73.54% to $3.5 million in 2025, then decreased by 3.21% to $3.4 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $3.4 million, $3.5 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 3.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.41 Mn |
| Dec 31, 2025 | 3.52 Mn |
| Sep 30, 2025 | 3.96 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Mar 31, 2025 | 6.00 Mn |
| Dec 31, 2024 | 13.31 Mn |
| Sep 30, 2024 | 13.24 Mn |
| Jun 30, 2024 | 4.08 Mn |
| Mar 31, 2024 | 5.53 Mn |
| Dec 31, 2023 | 6.07 Mn |
| Sep 30, 2023 | 10.35 Mn |
| Jun 30, 2023 | 18.81 Mn |
| Mar 31, 2023 | 28.68 Mn |
| Dec 31, 2022 | 2.60 Mn |
| Sep 30, 2022 | 361,000.00 |
| Jun 30, 2022 | 316,000.00 |
| Mar 31, 2022 | 5.24 Mn |
| Dec 31, 2021 | 5.31 Mn |
| Sep 30, 2021 | 415,000.00 |
| Jun 30, 2021 | 616,000.00 |
| Mar 31, 2021 | 738,000.00 |
| Dec 31, 2020 | 748,000.00 |
| Sep 30, 2020 | 515,000.00 |
| Jun 30, 2020 | 447,000.00 |
| Mar 31, 2020 | 535,000.00 |
| Dec 31, 2019 | 596,000.00 |
| Sep 30, 2019 | 656,000.00 |
| Jun 30, 2019 | 108,000.00 |
| Mar 31, 2019 | 106,366.00 |
| Dec 31, 2018 | 33,384.00 |
| Sep 30, 2018 | 296,206.00 |
| Jun 30, 2018 | 495,095.00 |
| Mar 31, 2018 | 4.70 Mn |
| Dec 31, 2017 | 5.16 Mn |
| Sep 30, 2017 | 5.43 Mn |
| Jun 30, 2017 | 5.70 Mn |
| Mar 31, 2017 | 5.95 Mn |
| Dec 31, 2016 | 6.15 Mn |
| Sep 30, 2016 | 6.33 Mn |
| Jun 30, 2016 | 6.41 Mn |
| Mar 31, 2016 | 6.75 Mn |
| Dec 31, 2015 | 6.69 Mn |
| Sep 30, 2015 | 6.12 Mn |
| Jun 30, 2015 | 5.15 Mn |
| Mar 31, 2015 | 3.11 Mn |
| Dec 31, 2014 | 1.99 Mn |
| Sep 30, 2014 | 1.57 Mn |
| Jun 30, 2014 | 1.10 Mn |
| Mar 31, 2014 | 285,764.00 |
| Dec 31, 2013 | 286,650.00 |
| Sep 30, 2013 | 287,536.00 |
| Jun 30, 2013 | 288,422.00 |
| Mar 31, 2013 | 288,717.00 |
| Mar 31, 2012 | 1,945.00 |